1.Davies M. The cardiomyopathies: an overview. Heart. 2000; 83(4): 469-674.
2.Wexler R, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview. Am Fam Physician. 2009; 79(9): 778-784.
3.Wong F. Cirrhotic cardiomyopathy. Hepatol Int. 2009; 3(1): 294-304.
4.Møller S, Lee SS. Cirrhotic cardiomyopathy. J Hepatol. 2018; 69(4): 958--960.
5.Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013; 34(36): 2804-2811.
6.Regan TJ, Levinson GE, Oldewurtel HA, Frank MJ, Weisse AB, Moschos CB. Ventricular function in noncardiacs with alcoholic fatty liver: role of ethanol in the production of cardiomyopathy. J Clin Invest. 1969; 48(2): 397-407.
7.Ingles AC, Hernandez I, Garcia-Estan J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol Heart Circ Physiol. 1991; 260(6): H1912-H7.
8.Pacher P, Bátkai S, Kunos G. Cirrhotic cardiomyopathy: an endocannabinoid connection? Br J Pharmacol. 2005; 146(3): 313-314.
9.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014; 8(3): 308-315.
10.Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy. Gastroenterol Clin Biol. 2002; 26: 842–847.
11.Gaskari SA, Honar H, Lee SS. Therapy insight: cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(6): 329-337.
12.van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol. 1996; 24(6):747-452.
13.Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology. 2001; 121(5):1209-218.
14.Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol. 1984; 65(3): 305-311.
15.Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). Int J Complement Altern Med. 2003; 9(1): 161-168.
16.Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta medica. 1991; 57(01): 1-7.
17.Nisenberg O. Targeted Overexpression of S-adenosylmethionine Decarboxylase in Murine Hearts. 2003.
18.Foti MC. Antioxidant properties of phenols. J Pharm Pharmacol. 2007; 59(12): 1673-1685.
19.Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys. 2012; 49(5): 306-315.
20.Yu W, Wu J, Cai F, Xiang J, Zha W, Fan D. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One. 2012; 7(12): e52013.
21.Hewlings SJ, Kalman DS. Curcumin: a review of its’ effects on human health. Foods. 2017; 22; 6(10). pii: E92.
22.Lavan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 2003; 21(10): 1184-1191.
23.Cavalcanti A, Shirinzadeh B, Freitas Jr RA, Hogg T. Nanorobot architecture for medical target identification. Nanotechnology. 2007; 19(1): 015103.
24.Mitra AK, Cholkar K, Mandal A. Emerging nanotechnologies for diagnostics, drug delivery and medical devices: William Andrew; 2017.
25.Rezayat S. The protective effect of nano-curcumin in experimental model of acute pancreatitis: The involvement of TLR4/NF-kB pathway. Nanomed J. 2018; 5(3): 138-143.
26.Dolati S, Ahmadi M, Aghebti-Maleki L, Nikmaram A, Marofi F, Rikhtegar R. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacol Rep. 2018; 70(6): 1158-1167.
27.Tarcin O, Basaranoglu M, Tahan V, Tahan G, Sücüllü I, Yilmaz N. Time course of collagen peak in bile duct-ligated rats. BMC Gastroenterol. 2011;11(1): 45.
28.Mani AR, Ippolito S, Ollosson R, Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis. Hepatology. 2006; 43(4): 847-856.
29.Garrido M, Escobar C, Zamora C, Rejas C, Varas J, Párraga M, et al. Bile duct ligature in young rats: A revisited animal model for biliary atresia. Eur J Histochem. 2017; 61(3): 2803.
30.Yang Y, Chen B, Chen Y, Zu B, Yi B, Lu K. A comparison of two common bile duct ligation methods to establish hepatopulmonary syndrome animal models. Lab Anim. 2015; 49(1): 71-79.
31.Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct‐ligated rats. Br J Pharmacol. 2005; 146(3): 315-323.
32.Bruck R, Ashkenazi M, Weiss S, Goldiner I, Shapiro H, Aeed H. Prevention of liver cirrhosis in rats by curcumin. Liver Int. 2007; 27(3): 373-383.
33.Li L, Duan M, Chen W, Jiang A, Li X, Yang J, et al. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J Transl Med. 2017; 15(1): 111.
34.Moore K, Roberts LJ. Measurement of lipid peroxidation. Free Radic Res. 1998; 28(6): 659-671.
35.Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95(2): 351-358.
36.Ighodaro O, Akinloye O. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alex J Med. 2018; 54(4): 287-293.
37.Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M. Doxorubicin‐induced congestive heart failure in adults. Cancer. 1985; 56(6): 1361-1365.
38.Yarmohmmadi F, Rahimi N, Faghir-Ghanesefat H, Javadian N, Abdollahi A, Pasalar P. Protective effects of agmatine on doxorubicin-induced chronic cardiotoxicity in rat. Eur J Pharmacol. 2017; 796: 39-44.
39.Sheibani M, Nezamoleslami S, Faghir-Ghanesefat H, hossein Emami A, Dehpour AR. Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. Cancer Chemother Pharmacol. 2020:1-9.
40.Radu R, Bold A, Pop O, Mălăescu D, Gheorghişor I, Mogoantă L. Histological and immunohistochemical changes of the myocardium in dilated cardiomyopathy. Rom J Morphol Embryol. 2012; 53(2): 269-275.
41.Timoh T, Protano M, Wagman G, Bloom M, Vittorio T, editors. A perspective on cirrhotic cardiomyopathy. Transplantation proceedings; 2011: Elsevier.
42.Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F. Cirrhotic cardiomyopathy: a cardiologist’s perspective. World J Gastroenterol. 2014; 20(42): 15492-15498.
43.Møller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol. 2013; 167(4): 1101-1108.
44.Liu H, Lee SS. Nuclear factor‐κB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int. 2008; 28(5): 640-648.
45.Sánchez-Fidalgo S, Cárdeno A, Villegas I, Talero E, de la Lastra CA. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol. 2010; 633(1-3): 78-84.
46.Bereswill S, Muñoz M, Fischer A, Plickert R, Haag L-M, Otto B, et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PloS one. 2010; 3;5(12): e15099..
47.Mošovská S, Petáková P, Kaliňák M, Mikulajová A. Antioxidant properties of curcuminoids isolated from Curcuma longa L. Acta Chimica Slovaca. 2016; 9(2): 130-135.
48.Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease: Springer; 2007. p. 105-125.
49.Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative medicine review. 2009; 14(2).
50.Hatamipour M, Sahebkar A, Alavizadeh SH, Dorri M, Jaafari MR. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iran J Basic Med Sci. 2019; 22(3): 282-289.
51.Javadi M, Khadem Haghighian H, Goodarzy S, Abbasi M, Nassiri‐Asl M. Effect of curcumin nanomicelle on the clinical symptoms of patients with rheumatoid arthritis: A randomized, double‐blind, controlled trial. Int J Rheum Dis. 2019; 22(10): 1857-1862.
52.Sundar Dhilip Kumar S, Houreld NN, Abrahamse H. Therapeutic potential and recent advances of curcumin in the treatment of aging-associated diseases. Molecules. 2018; 23(4): 835.
53.Rahimi HR, Nedaeinia R, Shamloo AS, Nikdoust S, Oskuee RK. Novel delivery system for natural products: Nano-curcumin formulations. Avicenna J Phytomed. 2016 Jul-Aug; 6(4): 383-398.
54.Fourlas CA, Alexopoulou AA. Cirrhotic cardiomyopathy. Hellenic J Cardiol. 2004; 45:114-120.
55.Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci. 2013; 58(10): 3029-3036.
56.Behrendt P, Preusse-Prange A, Klüter T, Haake M, Rolauffs B, Grodzinsky A. IL-10 reduces apoptosis and extracellular matrix degradation after injurious compression of mature articular cartilage. Osteoarthritis Cartilage. 2016; 24(11): 1981-1988.
57.Hofstetter C, Flondor M, Hoegl S, Muhl H, Zwissler B. Interleukin-10 aerosol reduces proinflammatory mediators in bronchoalveolar fluid of endotoxemic rat. Crit Care Med. 2005; 33(10): 2317-2322.
58.Hellenbrand DJ, Reichl KA, Travis BJ, Filipp ME, Khalil AS, Pulito DJ. Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury. J Neuroinflammation. 2019; 16(1): 93.
59.Khan J, Noboru N, Young A, Thomas D. Pro and anti-inflammatory cytokine levels (TNF-α, IL-1β, IL-6 and IL-10) in rat model of neuroma. Pathophysiology. 2017; 24(3): 155-159.
60.Mu W, Ouyang X, Agarwal A, Zhang L, Long DA, Cruz PE, et al. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol. 2005; 16(12): 3651-3660.
61.Amirshahrokhi K, Ghazi-Khansari M, Mohammadi-Farani A, Karimian G. Effect of captopril on TNF-α and IL-10 in the livers of bile duct ligated rats. Iranian J Immunol. 2010; 7(4): 247-251.
62.Niki E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors. 2008; 34(2): 171-180.
63.Gaweł S, Wardas M, Niedworok E, Wardas P. Malondialdehyde (MDA) as a lipid peroxidation marker. Wiadomosci lekarskie (Warsaw, Poland: 1960). 2004; 57(9-10): 453-455.
64.Wolf G. The discovery of the antioxidant function of vitamin E: the contribution of Henry A. Mattill. J Nutr. 2005; 135(3): 363-366.
65.Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacognosy reviews. 2010; 4(8): 118.
66.Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sánchez-Pérez P, Cadenas S, et al. Antioxidant responses and cellular adjustments to oxidative stress. Redox biology. 2015; 6: 183-197.
67.Hwang C, Sinskey AJ, Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. Science. 1992; 257(5076): 1496-502.
68.Wang X-L, Li T, Li J-H, Miao S-Y, Xiao X-Z. The effects of resveratrol on inflammation and oxidative stress in a rat model of chronic obstructive pulmonary disease. Molecules. 2017; 22(9): 1529.
69.Lebovitz RM, Zhang H, Vogel H, Cartwright J, Dionne L, Lu N. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proceedings of the National Academy of Sciences. 1996; 93(18): 9782-9787.